Vincerx Pharma Statistics
Total Valuation
Vincerx Pharma has a market cap or net worth of $21.77 million. The enterprise value is $18.79 million.
| Market Cap | 21.77M |
| Enterprise Value | 18.79M |
Important Dates
The next estimated earnings date is Monday, August 5, 2024, before market open.
| Earnings Date | Aug 5, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Vincerx Pharma has 29.53 million shares outstanding. The number of shares has increased by 1.00% in one year.
| Shares Outstanding | 29.53M |
| Shares Change (YoY) | +1.00% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 18.27% |
| Owned by Institutions (%) | 37.27% |
| Float | 23.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.72
| Current Ratio | 0.72 |
| Quick Ratio | 0.70 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -303.10% and return on invested capital (ROIC) is -2,190.86%.
| Return on Equity (ROE) | -303.10% |
| Return on Assets (ROA) | -168.40% |
| Return on Capital (ROIC) | -2,190.86% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$910,595 |
| Employee Count | 42 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -42.04% in the last 52 weeks. The beta is 1.11, so Vincerx Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | -42.04% |
| 50-Day Moving Average | 0.74 |
| 200-Day Moving Average | 1.68 |
| Relative Strength Index (RSI) | 50.45 |
| Average Volume (20 Days) | 237,233 |
Short Selling Information
The latest short interest is 433,167, so 1.47% of the outstanding shares have been sold short.
| Short Interest | 433,167 |
| Short Previous Month | 612,493 |
| Short % of Shares Out | 1.47% |
| Short % of Float | 1.86% |
| Short Ratio (days to cover) | 2.15 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -34.99M |
| Pretax Income | -38.25M |
| Net Income | -38.25M |
| EBITDA | -37.22M |
| EBIT | -38.25M |
| Earnings Per Share (EPS) | -$1.79 |
Balance Sheet
The company has $5.19 million in cash and $2.22 million in debt, giving a net cash position of $2.97 million or $0.10 per share.
| Cash & Cash Equivalents | 5.19M |
| Total Debt | 2.22M |
| Net Cash | 2.97M |
| Net Cash Per Share | $0.10 |
| Equity (Book Value) | -622,000 |
| Book Value Per Share | -0.02 |
| Working Capital | -2.96M |
Cash Flow
| Operating Cash Flow | -35.10M |
| Capital Expenditures | n/a |
| Free Cash Flow | -35.10M |
| FCF Per Share | -$1.64 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vincerx Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.00% |
| Shareholder Yield | -1.00% |
| Earnings Yield | -175.70% |
| FCF Yield | -161.26% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -16.77% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |